NCT00545311View on ClinicalTrials.gov

Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

July 31, 2007

Study Completion Date

October 31, 2007

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

NVA237

DRUG

NVA237

DRUG

NVA237

DRUG

NVA237

DRUG

Placebo

Trial Locations (4)

Unknown

Novartis Investigative site, Copenhagen

Novartis investigative site, Berlin

Novartis investigative site, Mönchengladbach

Novartis Investigative Site, Munich

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY